News
IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Company’s T cell therapy demonstrates an 86%
Therma Bright gründet neue Gesellschaft Torion Biosciences zur Entwicklung seines COVID-19-Antigen-Schnelltests CoviSafe™
- Therma Bright prüft Ausgliederung seiner Verbraucherprodukte
Toronto, Ontario--(4. November 2020) – Therma Bright Inc. (TSXV: THRM) („Therma Bright“ oder das „Unternehmen“), ein
Therma Bright Creates New Venture, Torion Biosciences to Develop its COVID-19 Rapid Antigen Test, CoviSafe™
- Therma Bright Investigates Spinoff of its Consumer Products
Toronto, Ontario--(November 4, 2020) – Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a
Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced topline data from the Phase 2/3 AUDREY™ clinical
Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to
IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
NeutriSci Provides Update on Product Launch in Japan
Vancouver, British Columbia – October 28, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
NeutriSci informiert über die Produkteinführung in Japan
Vancouver, British Columbia – 28. Oktober 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) – ein innovatives
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic Dermatology
Vancouver, Canada – October 26, 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical study using .2% TFC-1067 and conducted
Sirona Biochems klinische Studie zu TFC-1067 zur Veröffentlichung im Journal of Cosmetic Dermatology angenommen
Vancouver, Kanada – 26. Oktober 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (US-OTC: SRBCF) („Sirona“) freut sich bekannt zu geben, dass die von Dr. Zoe Draelos von der Firma
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
Therma Bright und Orpheus Medica überführen den Speichel-Schnelltest CoviSafe™ in die formelle Produktentwicklungsphase
- Erfolgreicher Abschluss der Machbarkeitsstudien, gefolgt von der Beauftragung von nanoComposix zur beschleunigten Entwicklung von CoviSafe™
Toronto, Ontario--(21. Oktober 2020)
Therma Bright and Orpheus Medica Advance CoviSafe™ Rapid Saliva Test to Formal Product Developmental Phase
- Successful Completion of the feasibility Studies followed by engagement of nanoComposix to accelerate the development of CoviSafe™
Toronto, Ontario--(October 21, 2020) –
EnWave Announces Normal Course Issuer Bid
Vancouver, B.C., October 19, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave,” or the "Company” - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine-sales
EnWave kündigt Aktienrückkaufprogramm an
Vancouver, B.C., 19. Oktober 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine
IMV Inc. Re-establishes At-the-Market Facility
IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated October 16
NeutriSci Enters the Second Highest Grossing Market with New Distribution in the State of Washington
Vancouver, British Columbia – October 15, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
NeutriSci betritt mit dem US-Bundesstaat Washington den Markt mit den zweithöchsten Cannabis-Umsätzen weltweit
Vancouver (British Columbia), 15. Oktober 2020 - NeutriSci International Inc. (TSX-V: NU, OTCQB: NRXCF, Frankfurt: 1N9) („NeutriSci“ oder das „Unternehmen“, ein innovatives
Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that
EnWave unterzeichnet Technologiebewertungsabkommen inklusive Lizenzoptionen mit amerikanischem Industriehanfproduzenten
Vancouver, B.C., 14. Oktober 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
EnWave Signs Technology Evaluation and License Option Agreement with American Industrial Hemp Producer
Vancouver, B.C., October 14, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for
Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skin Care Compound TFC-1067
Vancouver, Canada - October 13, 2020 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with a top 10 global